# Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

> **NCT03634150** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Immune System Key Ltd**

## Conditions studied

- Metastatic Ovarian Cancer
- Triple Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.

## Key facts

- **NCT ID:** NCT03634150
- **Lead sponsor:** Immune System Key Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-06
- **Primary completion:** 2020-04-21
- **Final completion:** 2020-04-21
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Patients were screened but not enrolled
- **Last updated:** 2021-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03634150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03634150, "Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03634150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*